Laberon

Beclometasone dipropionate, the active ingredient in Laberon, is a corticosteroid/long‑acting β2‑agonist combination presented as an inhalation aerosol for inhalation use. It is indicated for long‑term maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adults. The formulation delivers both anti‑inflammatory and bronchodilatory effects, helping to reduce airway hyper‑responsiveness and improve lung function, thereby decreasing the frequency of exacerbations and the need for rescue medication.

GNH USA supplies Laberon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Laberon, a corticosteroid/long‑acting β2‑agonist inhaler, is used in the management of chronic respiratory diseases.

- Asthma: provides long‑term control of symptoms and reduces the risk of exacerbations. - COPD: improves airflow limitation and decreases symptom burden in maintenance therapy. - Exercise‑induced bronchoconstriction: may be used for prevention in patients already on maintenance therapy.

Common Side Effects: - Oral thrush or candidiasis - Hoarseness or dysphonia - Cough or throat irritation - Headache - Tremor or shakiness - Palpitations

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression with systemic effects - Severe allergic reactions (anaphylaxis) - Pneumonia or respiratory infections - Cardiac arrhythmias - Hyperglycaemia in susceptible patients

Before initiating therapy, consider the following precautions: - Assess for active respiratory infections: treat infection before starting. - Monitor for oral candidiasis: advise rinsing mouth after inhalation. - Evaluate cardiovascular status: caution in patients with arrhythmias or hypertension. - Use the lowest effective dose: adjust based on symptom control. - Avoid abrupt discontinuation: taper if long‑term high‑dose use. - Store at room temperature: keep in original container, protect from moisture and heat.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and provoke bronchospasm. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic corticosteroid exposure. - Other inhaled or systemic corticosteroids: risk of additive glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalaemia when combined with β2‑agonists. - Sympathomimetic agents (e.g., epinephrine): additive cardiovascular stimulation. - Ritonavir or other strong CYP3A4 inhibitors: monitor for increased side effects. - Fluconazole: may modestly raise systemic corticosteroid levels.